Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04433806
Other study ID # 19-010206
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 21, 2020
Est. completion date May 1, 2022

Study information

Verified date September 2022
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purposes of this study is to evaluate the feasibility of providing a community based referral to Mayo Clinic Employee and Community Health patients for weight loss.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date May 1, 2022
Est. primary completion date May 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Patients who are between 18-65 years of age - Patients who have a BMI between 25-39.9 kg/m2 - Ability to provide informed consent - Ability to complete the Diabetes Prevention Program including dietary and physical activity recommendations - Motivated to lose weight (assessed to be in the preparation or action stage) Exclusion Criteria: - Have used weight loss medications or participated in a weight loss program within the past 30 days. - Are currently enrolled in DPP or other ExercisAbilities weight loss programs - Are currently taking supplements known to affect weight. - Have had weight fluctuations of 20 pounds or more in the past 6 months (EMR check and self-report) - Have an active untreated clinically significant psychiatric condition (psychosis, bipolar disorder, or depression) - Are currently pregnant or breastfeeding, or are of child-bearing potential and are likely to become pregnant during the study (within the next 4 months following enrollment) - Have a history in the past 4 months of any major cardiovascular events including heart valve disease, cardiac arrhythmias, congestive heart failure, acute coronary syndrome, stroke, transient ischemic attack, or peripheral vascular disease - Have current uncontrolled hypertension (systolic > 160 mm Hg or diastolic > 95 mm Hg) documented on 2 separate occasions - Have clinically significant acute or chronic progressive or unstable neurologic, hepatic, renal, cardiovascular, lymphatic, respiratory, or metabolic disease (such as diabetes) or active cancer or are within 1 year of cancer remission - Have a known history of any condition or factor judged by the investigator/study team to preclude participation in the study or which might hinder adherence - Have any co-morbidity that is deemed exclusionary at the discretion of the provider.

Study Design


Intervention

Behavioral:
Referral to weight loss program
16 weeks Diabetes Prevention Program based weight loss program at a local community partner

Locations

Country Name City State
United States Mayo Clinic in Rochester Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Participants recruited Total number of participants recruited Through study completion, approximately 28 weeks
Primary Participants enrolled Total number of participants enrolled Through study completion, approximately 28 weeks
Primary Participants accrued Total number of participants accrued Through study completion, approximately 28 weeks
Primary Participants to withdrawn or terminate study participation Total number of participants to withdrawn or terminate study participation Through study completion, approximately 28 weeks
Secondary Participant satisfaction Measured using the self-reported Was It Worth It (WIWI) Questionnaire that uses a total of 13 questions that asks feedback on participants experience and satisfaction with the Mayo Clinic/ExercisAbilities weight loss program. At study completion, approximately 28 weeks
Secondary Staff satisfaction Measured using the self-reported ExercisAbilities Staff Survey (Post-Intervention) that uses a total of 3 questions to rate experience on a scale of very satisfied to extremely not satisfied. At study completion, approximately 28 weeks
Secondary Change in weight Change in participant's weight measure in kilograms (kg) Baseline, week 16, week 28
Secondary Change in Body Mass Index (BMI) Change in participant's BMI calculated by weight in kilograms divided by the square of height in meters (kg/m2) Baseline, week 16, week 28
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2

External Links